Seeking Therapeutics and Vaccine Innovations for Respiratory Infections

A global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations wishes to identify infectious disease therapeutics and vaccines in European institutes, for a select list of respiratory indications. 

Further information

Our client wishes to identify technologies, research projects and spinout companies at any stage of development - from basic research to Phase I - focusing on the treatment of specific respiratory infections via novel therapeutics or vaccines. Primarily of focus are the prevalent respiratory infections caused by Rhinovirus, Human Metapneumovirus (hMPV), Influenza and Respiratory Syncytial Virus (RSV).

Research interests

Priority will be given to opportunities and expertise directly relating to client interests, targeting each virus as listed below:

• RSV: teams or technology focussed on developing either a prophylactic vaccine, fusion inhibitors, N inhibitors, nucleoside or non-nucleoside polymerase inhibitors. Biologics with long half-lives targeting RSV.
• Rhinovirus: high priority interest in antivirals (e.g. capsid binding inhibitor, polymerase inhibitor)
• Influenza: teams or technology focussed on creating a universal prophylactic vaccine, or influenza inhibitors targeting viral replication via any of the three polymerase subunits PB1,PB2, or PA endonuclease. Biologics with long half-lives ideally targeting influenza A and B.
• hMPV: teams or technology focussed on developing hMPV enzyme inhibitors as antivirals

Jurisdictions of Interest

Only submissions from institutions in Europe, Africa and the Middle East will be considered.

Submission Information

Submission of one-page technology briefs and information on applicable pre- or post-spinout companies is encouraged. The submission form can be downloaded here.